Tamiflu Case Summary Tamiflu (generic name: oseltamivir) is an antiviral medication that works against most but not all strains of flu — it is not effective against flu strains that have become resistant to it. Used preventively during an outbreak‚ Tamiflu significantly reduces the likelihood of illness. Used as a treatment (if taken promptly after the onset of symptoms)‚ it may significantly reduce the duration and severity of illness. As the world’s health officials prepare for a pandemic
Premium Influenza
Roche Holding AG: Funding the Genentech Acquisition Financial Policy March 5‚ 2015 Morgan Ephriam Kristopher Kirkpatrick Jasmine White 1. Statement of the Problem In the case Roche Holding AG: Funding the Acquisition‚ Roche and Genentech are interested in an acquisition. Roche is acquiring about receiving all outstanding shares of Genentech. Roche Holding AG is a Switzerland-based pharmaceuticals and diagnostics company. It discovers‚ develops and provides diagnostic and therapeutic products
Premium Bond Discounted cash flow Finance
Advanced Corporate Finance Final Case: Roche 1 2 Reasons for Roche’s 100% ownership of Genentech Since Roche and Genentech both operate in the pharmaceutical industry‚ but still have their own specialty‚ they can benefit from a partnership. Roche owns a majority stake in Genentech since 1990 and since 2007‚ it owns 56% of Genentech. Genentech was founded in 1976‚ their focus lies on biotechnology in which they are the second largest firm of the world. Genentech had become an important
Premium Corporate finance Debt Finance
Judith Schrempf-Stirling Received: 17 August 2012 / Accepted: 5 April 2013 / Published online: 17 April 2013 Ó Springer Science+Business Media Dordrecht 2013 Abstract This case study discusses the economic‚ legal‚ and ethical considerations for conducting clinical trials in a controversial context. In 2010‚ pharmaceutical giant Roche received a shame award by the Swiss non-governmental organization Berne Declaration and Greenpeace for conducting clinical trials with organs taken from executed prisoners
Premium Human rights Organ transplant Pharmaceutical industry
moment‚ Roche has a share of 65.9 %. The plan is to buy the rest of the 44.1 % of shares‚ so this case is clearly a complete acquisition. The merger of Roche is clearly a horizontal takeover. Both firms focus on pharmaceutical research‚ where Roche is mainly focused on pharmaceuticals and mdedical diagnoses. Genentech is primarily focused on devevloping products based on gene splicing or recombinant DNA for diseases such as cancer and aids. The reason for a complete takeover could be that Roche is looking
Premium ABN AMRO Biotechnology DNA
1) Why is Roche seeking to buy the 44% of Genentech it does not own? From Roche’s point of view‚ what are the advantages of owning 100% of Genentech? What are the risks? Roche is looking at this acquisition as a source of internal growth; the advantages are for research reasons‚ cutting cost creating a synergy by eliminating duplication of efforts and having easily access to Genentech’s free cash flow optimizing tax issues. Some analyst are concern that Genentech would lose its independence
Premium Stock market Stock Shareholder
Case Sustainability Initiative at Roche Table of Contents Introduction 3 Sustainable development: the triple bottom line 3 Economic‚ social and environmental responsibility 3 Social responsibility: the key elements 5 Corporate Responsibility Innovation at Roche 5 What is corporate responsibility? 5 Corporate responsibility according to the Roche corporate brochure 6 Target of responsibility as reflected in reported organizational structures‚ policies and practices. 7 Gaining competitive
Premium Sustainability Corporate social responsibility Business ethics
Cipla v Roche – Generics Industry Rejoices! For the last two years‚ the Delhi High Court has been the battle ground for a pharmaceutical war between Roche and Cipla over Roche’s patent for the anticancer drug ‘erlotinib’‚ sold by Roche as ’Tarceva’. On 24 April 2009‚ the Division bench of the Delhi High Court dismissed Roche’s appeal against the refusal of a single judge to grant an injunction restraining Cipla from manufacturing‚ offering for sale‚ selling and exporting its generic version of ‘erlotinib’
Premium Patent application Patent Patentability
patented anti-cancer drug (Erlotinib or Tarceva) belonging to Roche. However‚ Cipla was disallowed to export to other countries (temporarily). Due to the inability of the plaintiff (Roche) to prove its contention‚ the judgement of the case was based on the grounds of “public interest” To force a judgement favouring the injunction on Cipla the plaintiff (Roche) had to contend on the following grounds‚ i) That it had a prima facie case ii) That the “balance of convenience” was in its favour iii)
Premium Prima facie Legal burden of proof Judgment
1 Roche 2013 results London‚ 30 January 2014 2 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’‚ ‘expects’‚ ‘anticipates’‚ ‘projects’‚ ‘intends’‚ ‘should’‚ ‘seeks’‚ ‘estimates’‚ ‘future’ or similar expressions or by discussion of‚ among other things‚ strategy‚ goals‚ plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking
Premium Cancer Oncology Tumor